The estimated Net Worth of Tito Serafini is at least $2.61 Million dollars as of 1 April 2024. Dr Serafini owns over 20,788 units of Atreca Inc stock worth over $3,927 and over the last 5 years he sold BCEL stock worth over $2,609,246.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Dr D BCEL stock SEC Form 4 insiders trading
Dr has made over 26 trades of the Atreca Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 20,788 units of BCEL stock worth $1,455 on 1 April 2024.
The largest trade he's ever made was selling 30,000 units of Atreca Inc stock on 4 March 2022 worth over $150,000. On average, Dr trades about 7,513 units every 44 days since 2019. As of 1 April 2024 he still owns at least 43,636 units of Atreca Inc stock.
You can see the complete history of Dr Serafini stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Tito A. Serafini Ph.D. biography
Dr. Tito A. Serafini Ph.D. is the Founder, Chief Strategy Officer & Director at Atreca Inc.
How old is Dr D?
Dr D is 58, he's been the Founder and Chief Strategy Officer & Director of Atreca Inc since . There are no older and 3 younger executives at Atreca Inc.
What's Dr D's mailing address?
Tito's mailing address filed with the SEC is , SUITE 100, CAMPBELL, CA, 95008.
Insiders trading at Atreca Inc
Over the last 5 years, insiders at Atreca Inc have traded over $4,571,843 worth of Atreca Inc stock and bought 6,001 units worth $76,740 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro..., and Harbor Master Investors (Ca.... On average, Atreca Inc executives and independent directors trade stock every 20 days with the average trade being worth of $991. The most recent stock trade was executed by John A Orwin on 11 April 2024, trading 1 units of BCEL stock currently worth $0.
What does Atreca Inc do?
atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/
What does Atreca Inc's logo look like?
Complete history of Dr Serafini stock trades at Atreca Inc
Atreca Inc executives and stock owners
Atreca Inc executives and other stock owners filed with the SEC include:
-
John A. Orwin,
Pres, CEO & Director -
Herbert C. Cross,
Chief Financial Officer -
Dr. Stephen Gould Ph.D.,
Chief Scientific Officer -
Dr. Jonathan Benjamin M.D., Ph.D.,
Sr. VP of Clinical Research -
Dr. Daniel Emerling,
Sr. VP of Research -
Courtney J. Phillips J.D.,
Gen. Counsel & Corp. Sec. -
Dr. Yann Chong Tan,
Chief Technologist -
Dr. Tito A. Serafini Ph.D.,
Founder, Chief Strategy Officer & Director -
Bros. Advisors Lpbaker Juli...,
-
Kristine M Ball,
Director -
David L. Lacey,
Director -
Philippe C Bishop,
Chief Medical Officer -
Tito Serafini,
-
Franklin M Berger,
Director -
Brian G Atwood,
Director -
Lawrence Steinman,
Director -
William Hewitt Robinson,
Director -
& Melinda Gates Foundation ...,
-
Group, Llc Green Jeremy Red...,
-
Harbor Master Investors (Ca...,
10% owner -
Bros. Advisors Lp Baker Bro...,
-
Guy Cavet,
Chief Technical Officer -
Norman Michael Greenberg,
Chief Scientific Officer -
Lindsey Rolfe,
Director -
Herb Cross,
Chief Financial Officer -
Lisa Lynn Decker,
Chief Business Officer -
Stacey Ma,
Director -
Stephen R Brady,
Director -
Stephen E Gould,
Chief Scientific Officer -
Phillips Courtney,
GENERAL COUNSEL & SECRETARY -
John A Orwin,
PRESIDENT & CEO